Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Hydrocodone | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Magnesium sulfate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Rapacuronium may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Mirtazapine | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Orphenadrine | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Pramipexole | Rapacuronium may increase the sedative activities of Pramipexole. |
| Ropinirole | Rapacuronium may increase the sedative activities of Ropinirole. |
| Rotigotine | Rapacuronium may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Rapacuronium. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Rapacuronium is combined with Sodium oxybate. |
| Suvorexant | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Rapacuronium. |
| Thalidomide | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Rapacuronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Capreomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Capreomycin. |
| Cyclosporine | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Cyclosporine. |
| Doxycycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Doxycycline. |
| Lymecycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Lymecycline. |
| Framycetin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Framycetin. |
| Clomocycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Clomocycline. |
| Quinine | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Quinine. |
| Vancomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Vancomycin. |
| Tigecycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Tigecycline. |
| Oxytetracycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Oxytetracycline. |
| Chloroquine | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Chloroquine. |
| Demeclocycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Demeclocycline. |
| Mecamylamine | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Mecamylamine. |
| Tobramycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Tobramycin. |
| Tetracycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Tetracycline. |
| Gentamicin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Gentamicin. |
| Etacrynic acid | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Etacrynic acid. |
| Quinidine | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Quinidine. |
| Metacycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Metacycline. |
| Netilmicin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Netilmicin. |
| Neomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Neomycin. |
| Streptomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Streptomycin. |
| Colistimethate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Colistimethate. |
| Kanamycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Kanamycin. |
| Rolitetracycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Rolitetracycline. |
| Magnesium oxide | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium oxide. |
| Magnesium cation | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium cation. |
| Paromomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Paromomycin. |
| Lincomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Lincomycin. |
| Ribostamycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Ribostamycin. |
| Geneticin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Geneticin. |
| Apramycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Apramycin. |
| Gentamicin C1a | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Gentamicin C1a. |
| Neamine | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Neamine. |
| Arbekacin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Arbekacin. |
| Viomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Viomycin. |
| Puromycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Puromycin. |
| Magnesium hydroxide | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium hydroxide. |
| Magnesium trisilicate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium trisilicate. |
| Magnesium chloride | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium chloride. |
| Magnesium acetate tetrahydrate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium acetate tetrahydrate. |
| Magnesium carbonate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium carbonate. |
| Magnesium citrate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium citrate. |
| Magnesium glycinate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium glycinate. |
| Magnesium Aluminum Silicate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium Aluminum Silicate. |
| Dihydrostreptomycin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Dihydrostreptomycin. |
| Hygromycin B | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Hygromycin B. |
| Sisomicin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Sisomicin. |
| Plazomicin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Plazomicin. |
| Magnesium silicate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium silicate. |
| Penimepicycline | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Penimepicycline. |
| Magnesium aspartate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium aspartate. |
| Isepamicin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Isepamicin. |
| Magnesium gluconate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium gluconate. |
| Magnesium orotate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium orotate. |
| Magnesium phosphate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium phosphate. |
| Magnesium acetate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium acetate. |
| Procainamide | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Procainamide. |
| Dantrolene | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Dantrolene. |
| Piperacillin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Piperacillin. |
| Magnesium stearate | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium stearate. |
| Colistin | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Colistin. |
| Aclidinium | The risk or severity of adverse effects can be increased when Rapacuronium is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Rapacuronium. |
| Mirabegron | The risk or severity of urinary retention can be increased when Rapacuronium is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Rapacuronium is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Rapacuronium. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Rapacuronium. |
| Tiotropium | The risk or severity of adverse effects can be increased when Rapacuronium is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Rapacuronium is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Rapacuronium is combined with Umeclidinium. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Rapacuronium. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Rapacuronium is combined with Glycopyrronium. |
| Spironolactone | Spironolactone may increase the neuromuscular blocking activities of Rapacuronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Rapacuronium is combined with Botulinum toxin type A. |
| Glucagon | Rapacuronium may increase the gastrointestinal motility reducing activities of Glucagon. |